Josh Mandel-Brehm Buys 6,551 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) CEO Josh Mandel-Brehm purchased 6,551 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was bought at an average cost of $1.65 per share, with a total value of $10,809.15. Following the acquisition, the chief executive officer owned 284,968 shares in the company, valued at $470,197.20. This represents a 2.35% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

CAMP4 Therapeutics Stock Up 12.2%

CAMP opened at $4.50 on Friday. The company has a market cap of $233.69 million, a price-to-earnings ratio of -1.91 and a beta of 0.22. CAMP4 Therapeutics Corporation has a 52-week low of $1.32 and a 52-week high of $7.75. The firm’s fifty day simple moving average is $4.02 and its two-hundred day simple moving average is $4.31.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.11). The company had revenue of $1.29 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. On average, research analysts forecast that CAMP4 Therapeutics Corporation will post -0.84 EPS for the current year.

Institutional Trading of CAMP4 Therapeutics

Hedge funds have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. purchased a new position in CAMP4 Therapeutics in the 4th quarter worth approximately $61,000. Jefferies Financial Group Inc. acquired a new position in shares of CAMP4 Therapeutics during the 4th quarter worth approximately $70,000. Bank of America Corp DE purchased a new stake in shares of CAMP4 Therapeutics in the fourth quarter valued at approximately $86,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of CAMP4 Therapeutics in the fourth quarter valued at approximately $115,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of CAMP4 Therapeutics in the fourth quarter valued at approximately $115,000.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Rodman & Renshaw initiated coverage on CAMP4 Therapeutics in a report on Tuesday, April 14th. They issued a “buy” rating and a $7.00 price objective on the stock. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and raised their target price for the company from $5.00 to $9.00 in a research report on Tuesday, June 16th. Chardan Capital set a $6.50 price target on CAMP4 Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Zacks Research cut CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 15th. Finally, Weiss Ratings downgraded CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 21st. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.36.

Trending Headlines about CAMP4 Therapeutics

Here are the key news stories impacting CAMP4 Therapeutics this week:

• Positive Sentiment: CMP-002 is advancing into human trials. CAMP4 received regulatory clearance in Australia and Argentina to begin a Phase 1/2 study of CMP-002, an antisense oligonucleotide therapy for SYNGAP1-related disorders. The double-blind, placebo-controlled trial is expected to enroll at least 30 children ages 2 to 18. This is a significant milestone because SYNGAP1-related disorder has no approved disease-modifying treatments. CAMP4 advances SYNGAP1 treatment into human trials
• Positive Sentiment: Insider buying may signal management confidence. CEO Josh Mandel-Brehm, CFO Kelly Gold, Director Richard A. Young and insider Yuri Maricich collectively bought 36,031 shares at an average price of $1.65. While the purchases were modest in dollar value, they increased the insiders’ ownership positions and may be viewed positively by investors. CAMP4 insider purchase filing
• Positive Sentiment: Recent financing improves development funding. CAMP4 raised approximately $50.1 million in the second closing of a private placement. The proceeds are intended to support CMP-002 and the company’s early-stage pipeline, with participation from institutional investors including Janus Henderson, Balyasny Asset Management, Vivo Capital and 5AM Ventures. CAMP4 private placement announcement
• Negative Sentiment: The capital raise is significantly dilutive. CAMP4 issued more than 10.7 million common shares and approximately 21.9 million pre-funded warrants at about $1.53 per share-equivalent. The expanded potential share count and discounted issuance could limit per-share upside despite extending the company’s cash runway.
• Neutral Sentiment: Clinical risk remains high. CMP-002’s move into a Phase 1/2 trial is encouraging, but the therapy is still investigational. Safety and efficacy results in humans could differ materially from preclinical findings, making future trial updates key catalysts for CAMP.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.